Last reviewed · How we verify
NCT02284711: SALPOVA
Impact of Salpingectomy on Ovarian Reserve
NA trial testing Bipolar electric energy in Laparoscopic Salpingectomy in 96 participants. Completed in 16 October 2020.
16 October 2020
Quick facts
| Lead sponsor | Hospices Civils de Lyon |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 96 |
| Start date | 9 March 2015 |
| Primary completion | 16 October 2020 |
| Estimated completion | 16 October 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- Bipolar electric energy
- ultrasound energy
Conditions studied
- Laparoscopic Salpingectomy — all drugs for Laparoscopic Salpingectomy →
Sponsor
Hospices Civils de Lyon — full company profile →
Who can join
18 and older, female only, with Laparoscopic Salpingectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Epithelial cancer of the ovaries is the most severe form of gynecologic cancer; a significant proportion of ovarian cancers originate from the Fallopian tube. Guidelines therefore now recommend systematically associating prophylactic salpingectomy to benign hysterectomy. The principal objective of the present study is to assess the impact of salpingectomy on ovarian reserve by anti-Müllerian hormone (AMH) assay and calculating the Doppler index of vascular resistance in the ovarian vessels. The secondary objective is to compare ovarian reserve results between two coagulation techniques used in salpingectomy: bipolar electric energy versus ultrasound. The study design is single-center, prospective, before-and-after, with open randomization between two groups defined by coagulation technique.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Hysterectomy with opportunistic salpingectomy versus hysterectomy alone.
van Lieshout LAM, Steenbeek MP, De Hullu JA, Vos MC, et al · · 2019 · cited 34× · PMID 31456223 · DOI 10.1002/14651858.cd012858.pub2
Verify or expand the search:
- PubMed search for NCT02284711
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hospices Civils de Lyon trials
Trials by the same sponsor.
- NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
- NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
- NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
- NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
- NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02284711 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
- Last refreshed: 2 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02284711.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing